cms.bioaccessla.com

Tag: site readiness

  • First-in-Human Trial Readiness in Latin America: The Cross-Functional Gate Before Submission

    First-in-Human Trial Readiness in Latin America: The Cross-Functional Gate Before Submission

    A first-in-human (FIH) study in Latin America can move quickly only when the sponsor’s evidence tells one consistent story. The protocol, risk analysis, investigator brochure or device dossier, informed-consent materials, ethics package, and import plan must describe the same intended use, population, procedure, and safeguards. If those documents drift apart, a fast regulatory pathway can turn into a long clarification cycle.

    Internal experience across early-stage programs shows that readiness is less about producing more pages and more about closing the handoffs between regulatory, clinical, quality, site, and supply-chain teams. This practical gate helps MedTech founders and regulatory directors test whether a study is ready for country submissions without relying on a single calendar estimate.

    1. Start with one study story

    Before country tailoring begins, write a concise study narrative that every contributor can use. State what the investigational device is, who will use it, for which patients, in what setting, and what the FIH study is designed to learn. Separate proof-of-principle or early-feasibility questions from claims that will require a later pivotal study or market authorization.

    Then link each major claim to evidence. A risk control in the technical file should appear in the protocol’s monitoring plan and, where relevant, in the training and consent materials. The primary endpoint should match the feasibility objective. The procedure described for the investigator should match the version assessed by the ethics committee. This simple traceability exercise exposes contradictions before an authority or committee has to ask about them.

    • Intended use: define the population, setting, operator, procedure, and boundaries of use.
    • Risk controls: show foreseeable hazards, mitigations, stopping rules, and escalation contacts.
    • Clinical objective: use a focused endpoint set that answers the early-stage question without promising more than the study can demonstrate.
    • Participant protection: connect eligibility, follow-up, adverse-event handling, and consent language to the risk profile.
    • Version control: maintain one controlled source for device specifications, protocol revisions, and country annexes.

    2. Map the regulatory and ethics lanes before filing

    Latin America is not one regulatory pathway. A country matrix should identify the competent authority, ethics route, submission format, required translations, import documentation, responsible local party, and the definition of a complete submission. It should also distinguish a statutory or published review period from a practical activation forecast that includes clarifications, contracts, training, and shipment.

    Brazil illustrates why this distinction matters. Law No. 14.874/2024 establishes a 30-business-day period for an ethics committee to issue its opinion after accepting a complete document set, and a 90-business-day ceiling for the health analysis of primary clinical-trial petitions covered by the law. Those provisions are useful planning inputs, but they do not eliminate sponsor work before acceptance or operational work after authorization. The official English translation of Law No. 14.874/2024 should be checked for scope and the current implementation context.

    Colombia requires a different document conversation. INVIMA’s clinical-investigation materials identify the technical and ethical information needed for medical-device studies and publish current forms for protocol evaluation, ethics-committee assessment, notifications, and periodic reports. The sponsor should confirm the latest checklist rather than reusing a prior country’s format. The INVIMA clinical-investigation page is the appropriate starting point for current requirements.

    3. Treat site and import readiness as submission evidence

    An approved protocol cannot enroll if the site cannot perform the procedure, protect participants, or receive the investigational product. Site feasibility should therefore be documented before submission, not treated as a post-approval procurement task. Confirm investigator experience, procedure volume, equipment, imaging or laboratory support, emergency coverage, data systems, and the site’s ability to meet the visit schedule.

    For an investigational device, also map the physical journey into the country. Identify the importer of record or other responsible local party, customs broker, shipping documents, product description, packaging, storage conditions, and receipt inspection. The receiving site should know who can release a shipment, where it will be stored, how it will be labeled, and how deviations will be documented. If those answers are missing, the regulatory package is operationally incomplete even when the PDF set looks finished.

    Use an owner-and-dependency map for each handoff. Regulatory owns the submission matrix; clinical owns protocol and endpoint consistency; quality owns controlled versions and deviation pathways; the site owns readiness evidence; and logistics owns import and delivery controls. A single accountable person should resolve conflicts rather than allowing parallel teams to submit different answers.

    4. Run a documented readiness gate

    Two weeks before the planned filing, hold a cross-functional gate with the country team and proposed site. The objective is not to read every page aloud. It is to test the few dependencies that can stop the study.

    • Traceability check: reconcile intended use, device configuration, endpoints, risks, and consent language across all core documents.
    • Completeness check: confirm forms, translations, signatures, fees, certificates, and local representative details for the target country.
    • Site check: verify staff training, equipment, standard operating procedures, safety escalation, and recruitment assumptions.
    • Import check: test the shipment dossier with the broker and receiving site before the first dispatch.
    • Clarification check: prepare an evidence map showing who will answer likely questions and how quickly.

    Record open items with an owner, due date, and submission impact. If a high-risk item is unresolved, move the filing date rather than hiding the issue inside an optimistic timeline. A short, coherent dossier usually creates more speed than a large dossier assembled in parallel without a common source of truth.

    Frequently asked questions

    What is the most common FIH readiness failure?
    Document inconsistency is a frequent failure: the protocol, device description, risk controls, and consent materials describe different versions of the study. A traceability matrix finds this before submission.

    Can a sponsor use the same dossier in every Latin American country?
    The scientific core can be reused, but country forms, translations, ethics routes, local responsibilities, and import rules require tailored annexes. Reuse controlled content; do not assume identical filing requirements.

    When should import planning begin?
    Begin during site selection and protocol planning. Shipment classification, local responsibility, customs documents, storage, and receipt procedures can affect the activation sequence and should be tested before authorization.

    For sponsors planning an early-stage MedTech study, the practical goal is a submission that regulators, ethics committees, investigators, and logistics partners can all execute from the same study story. That is the readiness gate that turns a promising FIH concept into a controllable Latin America launch plan.

  • Radiopharmaceutical Trials In Latin America: A Logistics Readiness Framework For Sponsors

    Radiopharmaceutical Trials in Latin America: A Logistics Readiness Framework for Sponsors

    Radiopharmaceutical and theranostics programs have accelerated globally, but their clinical execution has a unique constraint: you are not only running a trial — you are running a time-sensitive supply chain. In Latin America, that supply chain can be a competitive advantage when it is planned well, and a critical risk when it is treated as an afterthought.

    This article offers a practical logistics readiness framework for sponsors planning radiopharmaceutical clinical trials in Latin America. The goal is to help clinical and operational leaders identify failure modes early and design a deployment plan that matches the physics, not just the protocol.

    Why radiopharmaceutical logistics is different

    Radiopharmaceutical trials have “hard” operational constraints: isotope half-life, radiation safety controls, qualified hot lab capacity, imaging standardization, and tightly coordinated shipment windows. In addition, sponsors may need to coordinate with multiple stakeholders — manufacturer, radiopharmacy, courier, customs brokers, hospital nuclear medicine teams, and regulators — where each handoff introduces risk.

    Because of these constraints, a strong sponsor question is: Can we execute the chain reliably, repeatedly, and compliantly for every subject?

    A logistics readiness framework (4 pillars)

    Use the following four pillars to assess readiness before site activation.

    Pillar 1: Isotope supply and contingency planning

    • Primary supply route: Define the manufacturing source, batch release timing, and shipment windows that match enrollment cadence.
    • Secondary route: Identify a backup route for disruptions (transport restrictions, manufacturing delays, flight changes).
    • Buffer strategy: For short half-life isotopes, “buffer” often means operational flexibility (multiple shipment windows) rather than inventory.

    Pillar 2: Regulatory and permit architecture

    • Import permits and documentation: Confirm what must be approved before the first shipment, and what can be handled per-shipment.
    • Labeling and chain-of-custody: Ensure labels, documentation, and custody logs satisfy both radiation safety and clinical trial requirements.
    • Waste and radiation safety: Map disposal pathways and responsibilities with each site to avoid last-minute operational blocks.

    Pillar 3: Site infrastructure and workflow maturity

    • Hot lab capability: Validate equipment, personnel qualification, and SOPs for receipt, preparation, and administration.
    • Scheduling discipline: Radiopharmaceutical administration is scheduling-sensitive. Sites need reliable slot control and patient preparedness workflows.
    • Adverse event readiness: Ensure emergency procedures and escalation pathways are documented and rehearsed.

    Pillar 4: Imaging, dosimetry, and data standardization

    • Imaging protocol consistency: Standardize acquisition parameters and timing relative to administration.
    • Calibration and QA: Establish calibration schedules and quality checks to reduce inter-site variability.
    • Data transfer and review: Define secure transfer pathways, central reads (if used), and turnaround expectations.

    Common failure modes — and how to prevent them

    • Enrollment outpaces supply planning: Align recruitment targets to realistic shipment cadence and site throughput.
    • Customs and documentation surprises: Create country-specific shipment playbooks and run a “first shipment rehearsal.”
    • Inconsistent imaging: Use standardized checklists and training, and consider centralized QA early.
    • Site capability overestimation: Validate the workflow in practice, not only on paper. A site can be clinically excellent and still operationally unready for radiopharmaceutical constraints.

    FAQ

    1) What should we assess first when choosing Latin American countries for radiopharmaceutical trials?
    Start with isotope availability routes, hot lab capacity, and the country’s ability to support compliant import and radiation safety workflows. If those are weak, other advantages will not compensate.

    2) Are logistics risks higher in Latin America than in the U.S. or EU?
    They are different. Risks often relate to cross-border shipment orchestration and variability in infrastructure by site. With the right planning and experienced operators, sponsors can build reliable execution pathways.

    3) How do we prevent schedule failures due to isotope half-life constraints?
    Design your operational plan around the isotope clock: confirmed shipment windows, controlled scheduling, backup routes, and rapid communication workflows across all parties.

    Bottom line: Radiopharmaceutical clinical trials reward operational maturity. Sponsors that treat logistics as a core part of trial design — not a downstream task — can unlock faster, more reliable execution across Latin America.

  • Radiopharmaceutical Trials In Latin America: A Logistics Readiness Framework For Sponsors

    Radiopharmaceutical Trials in Latin America: A Logistics Readiness Framework for Sponsors

    Radiopharmaceutical and theranostics programs have accelerated globally, but their clinical execution has a unique constraint: you are not only running a trial — you are running a time-sensitive supply chain. In Latin America, that supply chain can be a competitive advantage when it is planned well, and a critical risk when it is treated as an afterthought.

    This article offers a practical logistics readiness framework for sponsors planning radiopharmaceutical clinical trials in Latin America. The goal is to help clinical and operational leaders identify failure modes early and design a deployment plan that matches the physics, not just the protocol.

    Why radiopharmaceutical logistics is different

    Radiopharmaceutical trials have “hard” operational constraints: isotope half-life, radiation safety controls, qualified hot lab capacity, imaging standardization, and tightly coordinated shipment windows. In addition, sponsors may need to coordinate with multiple stakeholders — manufacturer, radiopharmacy, courier, customs brokers, hospital nuclear medicine teams, and regulators — where each handoff introduces risk.

    Because of these constraints, a strong sponsor question is: Can we execute the chain reliably, repeatedly, and compliantly for every subject?

    A logistics readiness framework (4 pillars)

    Use the following four pillars to assess readiness before site activation.

    Pillar 1: Isotope supply and contingency planning

    • Primary supply route: Define the manufacturing source, batch release timing, and shipment windows that match enrollment cadence.
    • Secondary route: Identify a backup route for disruptions (transport restrictions, manufacturing delays, flight changes).
    • Buffer strategy: For short half-life isotopes, “buffer” often means operational flexibility (multiple shipment windows) rather than inventory.

    Pillar 2: Regulatory and permit architecture

    • Import permits and documentation: Confirm what must be approved before the first shipment, and what can be handled per-shipment.
    • Labeling and chain-of-custody: Ensure labels, documentation, and custody logs satisfy both radiation safety and clinical trial requirements.
    • Waste and radiation safety: Map disposal pathways and responsibilities with each site to avoid last-minute operational blocks.

    Pillar 3: Site infrastructure and workflow maturity

    • Hot lab capability: Validate equipment, personnel qualification, and SOPs for receipt, preparation, and administration.
    • Scheduling discipline: Radiopharmaceutical administration is scheduling-sensitive. Sites need reliable slot control and patient preparedness workflows.
    • Adverse event readiness: Ensure emergency procedures and escalation pathways are documented and rehearsed.

    Pillar 4: Imaging, dosimetry, and data standardization

    • Imaging protocol consistency: Standardize acquisition parameters and timing relative to administration.
    • Calibration and QA: Establish calibration schedules and quality checks to reduce inter-site variability.
    • Data transfer and review: Define secure transfer pathways, central reads (if used), and turnaround expectations.

    Common failure modes — and how to prevent them

    • Enrollment outpaces supply planning: Align recruitment targets to realistic shipment cadence and site throughput.
    • Customs and documentation surprises: Create country-specific shipment playbooks and run a “first shipment rehearsal.”
    • Inconsistent imaging: Use standardized checklists and training, and consider centralized QA early.
    • Site capability overestimation: Validate the workflow in practice, not only on paper. A site can be clinically excellent and still operationally unready for radiopharmaceutical constraints.

    FAQ

    1) What should we assess first when choosing Latin American countries for radiopharmaceutical trials?
    Start with isotope availability routes, hot lab capacity, and the country’s ability to support compliant import and radiation safety workflows. If those are weak, other advantages will not compensate.

    2) Are logistics risks higher in Latin America than in the U.S. or EU?
    They are different. Risks often relate to cross-border shipment orchestration and variability in infrastructure by site. With the right planning and experienced operators, sponsors can build reliable execution pathways.

    3) How do we prevent schedule failures due to isotope half-life constraints?
    Design your operational plan around the isotope clock: confirmed shipment windows, controlled scheduling, backup routes, and rapid communication workflows across all parties.

    Bottom line: Radiopharmaceutical clinical trials reward operational maturity. Sponsors that treat logistics as a core part of trial design — not a downstream task — can unlock faster, more reliable execution across Latin America.